Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.99 -0.43 (-2.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
From GLD To TSLA: Unlocking Today’s Best Trading Opportunities ↗
The week kicks off amidst significant market movements shaped by geopolitical and policy developments. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
9 Analysts Have This To Say About Intellia Therapeutics ↗
 
Via Benzinga
News headline image
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
News headline image
A Glimpse of Intellia Therapeutics's Earnings Potential ↗
 
Via Benzinga
News headline image
Looking Into Intellia Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
7 Analysts Have This To Say About Intellia Therapeutics ↗
 
Via Benzinga
News headline image
A Closer Look at Intellia Therapeutics's Options Market Dynamics ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? ↗
There's nothing bearish at all about what it reported recently. 
Via The Motley Fool
News headline image
This Beaten-Down Stock Could Soar by 354%, According to Wall Street ↗
Maybe the Street is a bit too optimistic on this one. 
Via The Motley Fool
News headline image
12 High-Growth Stocks That Could Deliver Parabolic Returns ↗
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
News headline image
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36. 
Via Benzinga
Topics Stocks
News headline image
Why Intellia Therapeutics Stock Plummeted by 20% Today ↗
Seemingly encouraging results from the lab were met with some notable skepticism. 
Via The Motley Fool
News headline image
3 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Expert Ratings For Intellia Therapeutics ↗
 
Via Benzinga
News headline image
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday? ↗
Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses. 
Via Benzinga
News headline image
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street ↗
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility. 
Via The Motley Fool
News headline image
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street ↗
These stocks haven't performed well this year. 
Via The Motley Fool
News headline image
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk ↗
The Ark Invest portfolio is known for taking aggressive bets. 
Via The Motley Fool
News headline image
3 Gene Editing Stocks with Potential to Transform Medicine ↗
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. 
Via InvestorPlace
News headline image
NTLA Stock Earnings: Intellia Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗
NTLA stock results show that Intellia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The popular growth-stock investor added to these three existing positions on Wednesday. 
Via The Motley Fool
News headline image
7 Biotech Stocks to Keep on Your Clinical Radar ↗
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
News headline image
3 Gene Editing Stocks That Could Grow Your Wealth ↗
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks. 
Via InvestorPlace
News headline image
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition ↗
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
News headline image
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
3 Profitable CRISPR Stocks Earning Analysts’ Praise ↗
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
Via InvestorPlace
News headline image
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
News headline image
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger ↗
An improbable but serious risk facing the company's investors just got minimized. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.